Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Studio di fase I/II delle cellule T autologhe per esprimere i recettori delle cellule T (TCR) in soggetti con tumori solidi

3 novembre 2026 aggiornato da: Alaunos Therapeutics

Studio di fase I/II sulle cellule T autologhe ingegnerizzate utilizzando il sistema della bella addormentata per esprimere i recettori delle cellule T (TCR) reattivi contro le mutazioni specifiche del cancro in soggetti con tumori solidi

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors. The study ended during Phase I Arm A after 8 subjects were treated. Arm B and Phase II were not initiated, and the maximum tolerated dose or recommended Phase II dose was not determined.

Panoramica dello studio

Stato

Terminato

Condizioni

Intervento / Trattamento

Descrizione dettagliata

A Phase I/II study of autologous T cells engineered using the Sleeping Beauty transposon/transposase system to express TCR(s) reactive against neoantigens in subjects with relapsed/refractory solid tumors.

Screening was initially conducted under TCR001-002. TCR001-201 Protocol Amendment 4, approved by the IRB on 20 January 2023 and implemented at the site in February 2023, incorporated HLA typing and tumor neoantigen screening into TCR001-201. Eligibility required a matching tumor mutation and HLA restriction represented in the Sponsor's clinical TCR library.

The Phase I part of this study is a prospective, open-label, dose-escalation study of TCR-T cell drug product in patients with progressive or recurrent solid tumors who have failed standard therapy. The Phase II part is a prospective, open-label, single dose portion of the study. The planned Phase II portion was to begin after determination of the maximum tolerated dose or recommended Phase II dose in Phase I. The program closed during Phase I Arm A before that determination. Arm B and Phase II were not initiated, and no subject received interleukin-2 under this study.

Subjects with one of the following histologically confirmed solid tumors will be included:

  • Cohort 1: Gynecologic cancer (e.g., ovarian, endometrial)
  • Cohort 2: Colorectal cancer
  • Cohort 3: Pancreatic cancer
  • Cohort 4: Non-small cell lung cancer (NSCLC); NSCLC includes but is not limited to squamous cell carcinoma, adenosquamous carcinoma or adenocarcinomas
  • Cohort 5: Cholangiocarcinoma

Subject must have a tumor mutation and HLA typing combination that matches to at least one of the following TCRs in the Alaunos' library (mutation & HLA type):

  • KRAS G12D & HLA-A*11:01
  • KRAS G12D & HLA-C*08:02
  • KRAS G12V & HLA-A*11:01
  • KRAS G12V & HLA-C*01:02
  • TP53 R175H & HLA-A*02:01
  • TP53 R175H & HLA-DRB1*13:01
  • TP53 R248W & HLA-A*68:01
  • TP53 Y220C & HLA-A*02:01
  • TP53 Y220C & HLA-DRB3*02:02
  • EGFR E746-A750del & HLA-DPA1*02:01, DPB1*01:01

Tipo di studio

Interventistico

Iscrizione (Effettivo)

8

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

    • Texas
      • Houston, Texas, Stati Uniti, 77030
        • MD Anderson Cancer Center

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Patients who have completed the HLA Typing and Tumor Neoantigen Identification Protocol (TCR001-002) and for whom a TCR(s) matching the subject's somatic mutation(s) and HLA type restriction combination is available in Alaunos' Clinical TCR library

  2. Patients who have previously received at least one line of standard systemic therapy for their advanced/metastatic cancer and have either progressed, recurred, or were intolerant to the previous treatment. Specifically:

    • Subgroup 1. Gynecologic cancers (i.e., ovarian or endometrial):

      1. Ovarian cancer
      2. Endometrial cancer
    • Subgroup 2. Colorectal cancer

    • Subgroup 3. Pancreatic cancer

    • Subgroup 4. Non-small cell lung cancer (NSCLC)

    • Subgroup 5. Cholangiocarcinoma

  3. Patients must have evaluable or measurable disease per RECIST 1.1 with at least one lesion that can be measured that is not the biopsied lesion.

  4. Patients must be able to provide written informed consent.

  5. Patients must be age ≥ 18 years.

  6. Clinical Performance Status of ECOG 0 or 1. Approval from the Alaunos Medical Monitor is required for ECOG of 2.

  7. Patient must be willing and able to provide written informed consent for the long-term follow-up protocol (TCR001-202) for up to 15 years post TCR-T Cell drug product infusion per FDA requirements.

  8. Adequate bone marrow reserves as assessed by the following hematology laboratory criteria:

  9. Adequate major organ system function

  10. A washout period must have elapsed since completion of any prior systemic therapy, and apheresis with guidelines as follows (windows other than what is listed below should be allowed only after consultation with the Medical Monitor); subjects' non-hematologic toxicities from any prior systemic therapy must have recovered to ≤ Grade 1 (with the exception of neuropathy and alopecia) or baseline prior to starting the protocol's therapy.

  11. Patients may have undergone minor surgical procedures or limited-field radiotherapy provided any major organ toxicities have recovered to ≤ Grade 1.

  12. Female patients must not be pregnant or breastfeeding.

Exclusion Criteria:

  1. Patients with known active CNS metastases
  2. Concurrent systemic steroid therapy
  3. Any form of primary immunodeficiency
  4. Patients who have decreased immune competence
  5. History of severe immediate hypersensitivity reaction to cyclophosphamide, fludarabine, aldesleukin or bendamustine
  6. Severe chronic respiratory condition
  7. History of a bleeding disorder or unexplained major bleeding diathesis
  8. Arm B Criteria only: Clinically significant patient history which in the judgment of the principal investigator (PI) would compromise the subject's ability to tolerate high-dose aldesleukin;
  9. Any major bronchial occlusion or bleeding not amenable to palliation.
  10. Patients with psychiatric illness/social situations at the time of treatment that would limit compliance with study requirements.
  11. Participants with known active, uncontrolled bacterial, fungal, or viral infection
  12. Patients with a prior history or concurrent malignancy
  13. Active unstable or clinically significant medical condition
  14. History of any major cardiovascular conditions within the past 6 months

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione sequenziale
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: TCR-T Cell Drug Product

Phase I: Dose-escalation of TCR-T Cell Drug Product

Phase II: Single dose of TCR-T Cell Drug Product after MTD/RP2D determine in Phase I portion of the study

Phase I:

Ascending dose, single Infusion of TCR+ Cells

Phase II:

Single infusion at the RP2D

Sperimentale: TCR-T Cell Drug Product with Aldesleukin (IL-2)

Phase I: Dose-escalation of TCR-T Cell Drug Product with Aldesleukin (IL-2)

Phase II: Single dose of TCR-T Cell Drug Product with Aldesleukin (IL-2) after MTD/RP2D determine in Phase I portion of the study

Phase I:

Ascending dose, single Infusion of TCR+ Cells

Phase II:

Single infusion at the RP2D

To support growth and activation of TCR-T cell drug product

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Number of Participants With Treatment-Emergent Adverse Events
Lasso di tempo: From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.

Treatment-emergent adverse events (TEAEs) were defined as any adverse event that began or worsened after initiation of lymphodepletion and up to 28 days following TCR-T cell infusion. TEAEs were coded using MedDRA and summarized by system organ class and preferred term, severity, and relationship to study treatment. Participants were followed for delayed or ongoing toxicities for up to 1 year.

From initiation of lymphodepletion through Day 28 after TCR-T cell infusion, and through long-term follow-up for up to 1 year.
Frequency of Dose Limiting Toxicities
Lasso di tempo: From Day 0 to Day 28 post TCR-T cell drug product infusion.

Number of participants experiencing DLTs, defined as specific adverse events attributable to the TCR-T cell drug product occurring within the first 28 days of infusion. DLTs include, but are not limited to, Grade 4 neutropenia lasting ≥ 14 days, Grade 4 thrombocytopenia, Grade 3 thrombocytopenia with significant bleeding, and ≥ Grade 3 febrile neutropenia with hemodynamic compromise. Non-hematologic DLTs include Grade 3 or 4 Cytokine Release Syndrome (CRS) that does not improve to Grade ≤ 2 within 72 hours, and Grade 3 Immune-effector cell-associated neurotoxicity syndrome (ICANS) that does not resolve to Grade ≤ 2 within 7 days, among others. The severity of adverse events will be graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

From Day 0 to Day 28 post TCR-T cell drug product infusion.
Determination of Maximum Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D)
Lasso di tempo: From Day 0 to Day 28 post TCR-T cell drug product infusion.

MTD/RP2D determination was planned using accelerated escalation followed by the Bayesian Optimal Interval (BOIN) design and the protocol dose-escalation, de-escalation and stopping rules. Overt-toxicity criteria included 2 or more DLTs and consideration of longer-term toxicity. The trial would stop if the lowest dose was eliminated for overt toxicity. Formal MTD/RP2D determination was not completed because the study closed during Phase I Arm A.

From Day 0 to Day 28 post TCR-T cell drug product infusion.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Feasibility of TCR-T Cell Drug Product Manufacturing
Lasso di tempo: From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks

Number of participants in each mutually exclusive leukapheresis and manufacturing disposition category. A full-scale run is a clinical drug-product manufacturing run; small-scale testing and cell enrichment or cryopreservation are not full-scale runs. All released products were infused. Final cell count and viability of released products are reported in separate outcome measures.

From apheresis collection to the release of the final TCR-T cell drug product for infusion, estimated to be approximately 5 weeks
TCR-T Cell Persistence
Lasso di tempo: Baseline through nominal Month 18 post-infusion.

Peripheral-blood TCR-T vector copy number (VCN) was measured by droplet digital PCR (ddPCR; LabCorp Drug Development) in copies per 1 × 10⁶ cells. Visits are nominal. One DL2 participant's nominal Day 28 and Week 6 samples were both collected on Day 44; the Month 18 sample was collected on Day 577. Samples after TCR001-201 exit were collected under TCR001-202 (NCT05292859). Summaries include quantifiable values only; not-detected and below-LLOQ values are excluded. NA indicates no quantifiable result. One post-dose Day 0 sample has identical copies/reaction and copies/mL values to another participant's sample; the copies per 1 × 10⁶ cells values differ. Sampling ended at disease progression, death or program closure.

Baseline through nominal Month 18 post-infusion.
Percent Change in TCR-T Cell Count From Post Dose to Day 28
Lasso di tempo: Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.

For each participant, percent change from the highest post-dose VCN (copies per 1 × 10⁶ cells, ddPCR) from Day 0 post-dose through Day 21 to the nominal Day 28 value: ((Day 28 - peak) / peak) × 100. A Day 28 value below the LLOQ was set to 0 (-100%).

Post-dose Day 0 through nominal Day 28; nominal Day 28 samples were collected on actual Days 27 to 44.
Final T-Cell Count in Released TCR-T Cell Drug Product
Lasso di tempo: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).

Final cell counts from the Certificate of Analysis for the released product administered to each participant. The two rows report total viable cells from the automated cell counter and final murine T-cell receptor-positive (mTCR+) cells from the Content-Calculation method, each in billions of cells. These are manufacturing results, not the administered dose. For participants with more than 1 manufacturing run, only the released lot is used.

At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
Viability of Released TCR-T Cell Drug Product
Lasso di tempo: At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).

Percent viability reported on the final Certificate of Analysis for the released TCR-T cell product administered to each participant. One released product per participant is summarized, including the second manufacturing run when that run supplied the infused product.

At release testing of the final infused lot before TCR-T cell infusion on Day 0; the lot was harvested 1 day before infusion (fresh product, 3 participants) or 30 to 156 days before infusion (cryopreserved product, 5 participants).
Protocol-Defined Duration of TCR-T Cell Persistence to the Last Quantifiable VCN Sample
Lasso di tempo: From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.

Per Protocol Section 15.3.4 and SAP Section 4.5.2, duration is the number of days from infusion (Day 0) to the last sample with VCN at or above the assay lower limit of quantification. This is an observed last-quantifiable-sample metric. Sampling stopped at different times because of disease progression, death or program closure, so it does not establish when TCR-T cells disappeared. Later ND or below-LLOQ samples do not extend this metric. Samples from TCR001-202 are included where applicable.

From infusion through available VCN follow-up to nominal Month 18; last quantifiable samples were on Days 21 to 180.

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Scott Kopetz, MD, PhD, MD Anderson

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 aprile 2022

Completamento primario (Effettivo)

30 settembre 2023

Completamento dello studio (Effettivo)

11 ottobre 2023

Date di iscrizione allo studio

Primo inviato

6 dicembre 2021

Primo inviato che soddisfa i criteri di controllo qualità

3 gennaio 2022

Primo Inserito (Effettivo)

18 gennaio 2022

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

9 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • TCR001-201

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .